This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Patients Expect Pharmaceutical Companies To Provide Services That Help Them Manage Their Health, Accenture Survey Finds

Stocks in this article: ACN

A new Accenture (NYSE: ACN) survey of 2,000 patients in the United States taking long-term, short-term or lifestyle medications found that the vast majority (76 percent) believe pharmaceutical companies should provide services that complement the products they provide.

The survey – Why Pharma Companies Can’t Ignore Patient Services – also uncovered significant gaps in the services that patients want and those that they are currently receiving. Those that do receive patient services – from participation in rewards programs to receipt of product information and financial assistance – value them greatly and are eager to use them. Yet the survey also indicates that for many customers these programs are not available.

While 63 percent of the patients surveyed say they want to participate in customer rewards programs, only 10 percent say they have been offered the opportunity to do so. According to the survey, other services that patients most expect or want but are not receiving are:

  • Financial assistance: 51 percent of patients want it, but only 10 percent receive it.
  • Measuring and tracking alerts, such as monitoring of blood glucose levels: 35 percent of patients want it, but only 20 percent receive it
  • Product information: 53 percent of patients want it, and 48 percent say they receive such information.

“The vast majority of patients surveyed don’t just want patient services – they expect them and are looking to pharmaceutical companies to be part of the solution. While many patient services are underserved, those who receive services are very satisfied with them,” said Shawn Roman, managing director in Accenture’s Life Sciences industry group.

Roman adds, “This indicates there is tremendous opportunity for pharmaceutical companies to become more engaged with the patients they treat and truly understand how to help deliver a better patient outcome. Our survey findings show that this process can start early, with three out of four (74 percent) saying that outreach by pharmaceutical companies to patients should be initiated as soon as patients start taking a medication.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs